Open AccessNeoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial
Author(s) -
Carmen J. Allegra,
Greg Yothers,
Michael J. O’Connell,
Robert W. Beart,
Timothy F. Wozniak,
Henry C. Pitot,
Anthony F. Shields,
Jerome C. Landry,
David P. Ryan,
Amit Arora,
Lisa Evans,
Nathan Bahary,
Gamini S. Soori,
Janice F. Eakle,
John M. Robertson,
Dennis F. Moore,
Michael Russell Mullane,
Benjamin T. Marchello,
Patrick J. Ward,
Saima Sharif,
Mark S. Roh,
Norman Wolmark
Publication year - 2015
Publication title -
jnci journal of the national cancer institute
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.797
H-Index - 356
eISSN - 1460-2105
pISSN - 0027-8874
DOI - 10.1093/jnci/djv248
Subject(s) - capecitabine , oxaliplatin , medicine , clinical endpoint , colorectal cancer , hazard ratio , oncology , radiation therapy , randomized controlled trial , surgery , cancer , confidence interval
National Surgical Adjuvant Breast and Bowel Project R-04 was designed to determine whether the oral fluoropyrimidine capecitabine could be substituted for continuous infusion 5-FU in the curative setting of stage II/III rectal cancer during neoadjuvant radiation therapy and whether the addition of oxaliplatin could further enhance the activity of fluoropyrimidine-sensitized radiation.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom